Technology evaluation: Colostrinin (ReGen)
Rattray, M. (2005) Technology evaluation: Colostrinin (ReGen). Current Opinion in Molecular Therapeutics, 7 (1). pp. 78-84. ISSN 1464-8431
Full text not archived in this repository.
Official URL: http://www.ncbi.nlm.nih.gov/pubmed/15732533
ReGen Therapeutics is developing Colostrinin, a polypeptide complex derived from ovine colostrums, for the potential treatment of Alzheimer's disease. The compound is currently undergoing phase II clinical trials.